Hormone therapy as a management strategy for lung metastasis after 5 years of endometrial cancer: A case report and literature review.

Related Articles

Hormone therapy as a management strategy for lung metastasis after 5 years of endometrial cancer: A case report and literature review.

Medicine (Baltimore). 2017 Dec;96(51):e9223

Authors: Zhao H, Yao Y, Yang H, Ma D, Chen A

Abstract
RATIONALE: Endometrial cancer patients with lung metastases are rare, and more rarely with long-term management of progesterone after recurrence.
PATIENT CONCERNS: Informed consent of the patients and their families.
DIAGNOSES: Endometrial cancer (IVB) (Refer to 2009 FIGO stag of endometrial cancer).
INTERVENTIONS: the patient was treated with Megestrol Acetate Dispersible Tablets (trade name Yilizhi), 160 mg, orally, once daily, without interruption.
OUTCOMES: The patient has been treated with progesterone therapy for stable conditions and her survival time is already roughly a decade (December 2006-October 2016).
LESSONS: Hormone therapy may as a long-term management for hormone receptor-positive patients with recurrent endometrial cancer.

PMID: 29390473 [PubMed - indexed for MEDLINE]

http://ift.tt/2BYbYFK